How to treat androgenetic alopecia – the most common form of hair loss. A review
DOI:
https://doi.org/10.12775/JEHS.2024.73.51729Keywords
Androgenetic alopecia, male pattern hair loss, female pattern hair loss, androgens, health, hairAbstract
Introduction and purpose
Androgenetic alopecia (AGA) is one of the most common causes of baldness worldwide. It affects up to 80% of men by the age of 70 and up to 40% of postmenopausal women. In AGA etiology and pathogenesis, the three essential components play a key role - genetic inheritance, patient age and hormonal effects of androgens. In the following review, we have described the available FDA-approved and off-label treatments for AGA, along with their efficacy and potential side effects that should always be considered to prevent treatment discontinuation by the patients.
The state of knowledge
The pathogenesis of AGA is based on inherited dihydrotestosterone (DHT) sensitivity in the scalp skin, which leads to progressive hair loss. The literature documents the effectiveness of several treatments with different mechanisms of action in AGA therapy, but only topical minoxidil and oral finasteride gained FDA approval so far. Minoxidil acts by the blood vessels dilatation that increases the flow of oxygenated and growth factor-enriched blood to the hair follicles in the skin. 5-alpha reductase inhibitors, such as finasteride and dutasteride are another threapeutic option. Thy act by the inhibition of 5-alpha reductase, the enzyme which converts testosterone to DHT - the main causative agent of androgenetic alopecia. Recently, topical applications of minoxidil and finasterid, along with completely new emerging treatments for androgenetic alopecia are gaining popularity among doctors and patients.
Summary
This review describes current treatments for AGA, considering their efficacy, optimal doses, and the most common side effects. An important fact to emphasise is that androgenetic alopecia is based on a genetic predisposition, and treatment requires long-term use. For this reason, when choosing a medication, it is essential to cooperate with the patient and combine different therapeutic methods to achieve the desirable outcome while avoiding adverse reactions.
References
Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al. Androgenetic alopecia: a review. Endocrine [Internet]. 2017 Jul 1 [cited 2024 May 25];57(1):9–17. Available from: https://pubmed.ncbi.nlm.nih.gov/28349362/
Severi G, Sinclair R, Hopper JL, English DR, McCredie MRE, Boyle P, et al. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. Br J Dermatol [Internet]. 2003 Dec [cited 2024 May 25];149(6):1207–13. Available from: https://pubmed.ncbi.nlm.nih.gov/14674898/
Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs [Internet]. 2023 Jun 1 [cited 2024 May 25];83(8):701–15. Available from: https://pubmed.ncbi.nlm.nih.gov/37166619/
Herskovitz I, Tosti A. Female pattern hair loss. Int J Endocrinol Metab [Internet]. 2013 [cited 2024 May 25];11(4). Available from: https://pubmed.ncbi.nlm.nih.gov/24719635/
Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother [Internet]. 2010 Jun [cited 2024 May 25];11(8):1295–304. Available from: https://pubmed.ncbi.nlm.nih.gov/20426708/
Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc [Internet]. 2003 [cited 2024 May 25];8(1):24–7. Available from: https://pubmed.ncbi.nlm.nih.gov/12894991/
Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol [Internet]. 1998 [cited 2024 May 23];39(4 Pt 1):578–89. Available from: https://pubmed.ncbi.nlm.nih.gov/9777765/
Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science [Internet]. 1974 [cited 2024 May 23];186(4170):1213–5. Available from: https://pubmed.ncbi.nlm.nih.gov/4432067/
Chumlea WC, Rhodes T, Girman CJ, Johnson-Levonas A, Lilly FRW, Wu R, et al. Family history and risk of hair loss. Dermatology [Internet]. 2004 [cited 2024 May 25];209(1):33–9. Available from: https://pubmed.ncbi.nlm.nih.gov/15237265/
Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci [Internet]. 1951 [cited 2024 May 23];53(3):708–28. Available from: https://pubmed.ncbi.nlm.nih.gov/14819896/
Sharma AN, Michelle L, Juhasz M, Muller Ramos P, Atanaskova Mesinkovska N. Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. Int J Dermatol [Internet]. 2020 Aug 1 [cited 2024 May 20];59(8):1013–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32516434/
Villani A, Fabbrocini G, Ocampo-Candiani J, Ruggiero A, Ocampo-Garza SS. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. J Eur Acad Dermatol Venereol [Internet]. 2021 Jul 1 [cited 2024 May 20];35(7):1485–92. Available from: https://pubmed.ncbi.nlm.nih.gov/33660357/
Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Hermosa-Gelbard A, Moreno-Arrones OM, Fernandez-Nieto D, et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol [Internet]. 2019 Aug 1 [cited 2024 May 20];81(2):648–9. Available from: https://pubmed.ncbi.nlm.nih.gov/31054970/
Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol [Internet]. 2021 Mar 1 [cited 2024 May 21];84(3):737–46. Available from: https://pubmed.ncbi.nlm.nih.gov/32622136/
Dawber RPR, Rundegren J. Hypertrichosis in females applying minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol [Internet]. 2003 May [cited 2024 May 21];17(3):271–5. Available from: https://pubmed.ncbi.nlm.nih.gov/12702063/
Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol [Internet]. 2002 [cited 2024 May 21];46(2):309–12. Available from: https://pubmed.ncbi.nlm.nih.gov/11807448/
Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol [Internet]. 1999 [cited 2024 May 21];41(5 Pt 1):717–21. Available from: https://pubmed.ncbi.nlm.nih.gov/10534633/
Darchini-Maragheh E, Rees H, Moussa A, Bokhari L, Jones L, Sinclair R. Role of systemic minoxidil in the treatment of alopecia areata: A scoping review to direct future research. J Am Acad Dermatol [Internet]. 2024 Jun 1 [cited 2024 May 20];90(6). Available from: https://pubmed.ncbi.nlm.nih.gov/38423467/
Gupta AK, Talukder M, Shemer A. Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia. Expert Opin Pharmacother [Internet]. 2024 Jan 22 [cited 2024 May 20];25(2):139–47. Available from: https://www.tandfonline.com/doi/abs/10.1080/14656566.2024.2314087
Vastarella M, Cantelli M, Patrì A, Annunziata MC, Nappa P, Fabbrocini G. Efficacy and safety of oral minoxidil in female androgenetic alopecia. Dermatol Ther [Internet]. 2020 Nov 1 [cited 2024 May 22];33(6). Available from: https://pubmed.ncbi.nlm.nih.gov/32851744/
Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol [Internet]. 2024 [cited 2024 May 18]; Available from: https://pubmed.ncbi.nlm.nih.gov/38598226/
Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol [Internet]. 2020 Jan 1 [cited 2024 May 22];82(1):252–3. Available from: https://pubmed.ncbi.nlm.nih.gov/31473295/
Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol [Internet]. 2018 [cited 2024 May 22];57(1):104–9. Available from: https://pubmed.ncbi.nlm.nih.gov/29231239/
Erin C Callen, Chelsea O Church, Christina L Hernandez, Erin D Thompson. Stevens-Johnson syndrome associated with oral minoxidil: a case report. J Nephrol. 2007;20(1):91–3.
Karaoui LR, Chahine-Chakhtoura C. Fatal toxic epidermal necrolysis associated with minoxidil. Pharmacotherapy. 2009 Apr;29(4):460–7.
Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. J Clin Aesthet Dermatol [Internet]. 2016 Jul 1 [cited 2024 May 19];9(7):56. Available from: /pmc/articles/PMC5023004/
Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, et al. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther [Internet]. 2020 May 1 [cited 2024 May 20];33(3). Available from: https://pubmed.ncbi.nlm.nih.gov/32279398/
Frankel S. Study of the Food and Drug Administration files on Propecia: dosages, side effects, and recommendations. Arch Dermatol [Internet]. 1999 Mar 1 [cited 2024 May 23];135(3). Available from: https://pubmed.ncbi.nlm.nih.gov/10086445/
Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol [Internet]. 2010 [cited 2024 May 23];146(10):1141–50. Available from: https://pubmed.ncbi.nlm.nih.gov/20956649/
Kaiser M, Abdin R, Gaumond SI, Issa NT, Jimenez JJ. Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clin Cosmet Investig Dermatol [Internet]. 2023 [cited 2024 May 23];16:1387. Available from: /pmc/articles/PMC10239632/
Rossi A, Cantisani C, Scarnò M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther [Internet]. 2011 Jul [cited 2024 May 23];24(4):455–61. Available from: https://pubmed.ncbi.nlm.nih.gov/21910805/
Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol [Internet]. 2019 Jul 1 [cited 2024 May 23];58(7):759–76. Available from: https://pubmed.ncbi.nlm.nih.gov/30604525/
Shanshanwal S, Dhurat R. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol [Internet]. 2017 Jan 1 [cited 2024 May 24];83(1):47–54. Available from: https://pubmed.ncbi.nlm.nih.gov/27549867/
Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol [Internet]. 2014 [cited 2024 May 24];70(3):489-498.e3. Available from: https://pubmed.ncbi.nlm.nih.gov/24411083/
Choi S, Kwon SH, Sim WY, Lew BL. Long-term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with sustained efficacy. J Dermatol [Internet]. 2024 May 1 [cited 2024 May 24];51(5). Available from: https://pubmed.ncbi.nlm.nih.gov/38321615/
Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging [Internet]. 2019 [cited 2024 May 24];14:399–406. Available from: https://pubmed.ncbi.nlm.nih.gov/30863034/
Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat [Internet]. 2022 [cited 2024 May 25];33(7):2946–62. Available from: https://pubmed.ncbi.nlm.nih.gov/35920739/
Ntshingila S, Oputu O, Arowolo AT, Khumalo NP. Androgenetic alopecia: An update. JAAD Int [Internet]. 2023 Dec 1 [cited 2024 May 25];13:150. Available from: /pmc/articles/PMC10562178/
Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol [Internet]. 2009 Jan 1 [cited 2024 May 23];75(1):47–51. Available from: https://pubmed.ncbi.nlm.nih.gov/19172031/
Rossi A, Caro G. Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor blinded, 3-arm, pilot trial. J Cosmet Dermatol [Internet]. 2024 Feb 1 [cited 2024 May 23];23(2):502–9. Available from: https://pubmed.ncbi.nlm.nih.gov/37798906/
Gupta AK, Talukder M. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? J Cosmet Dermatol [Internet]. 2022 May 1 [cited 2024 May 23];21(5):1841–8. Available from: https://pubmed.ncbi.nlm.nih.gov/35238144/
Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol [Internet]. 2022 Mar 1 [cited 2024 May 18];158(3):266–74. Available from: https://pubmed.ncbi.nlm.nih.gov/35107565/
Aleissa M. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. Cureus [Internet]. 2023 Aug 16 [cited 2024 May 25];15(8). Available from: /pmc/articles/PMC10502763/
Friedman S, Schnoor P. Novel Approach to Treating Androgenetic Alopecia in Females With Photobiomodulation (Low-Level Laser Therapy). Dermatol Surg [Internet]. 2017 Jun 1 [cited 2024 May 25];43(6):856–67. Available from: https://pubmed.ncbi.nlm.nih.gov/28328705/
Egger A, Resnik SR, Aickara D, Maranda E, Kaiser M, Wikramanayake TC, et al. Examining the Safety and Efficacy of Low-Level Laser Therapy for Male and Female Pattern Hair Loss: A Review of the Literature. Skin Appendage Disord [Internet]. 2020 Sep 1 [cited 2024 May 25];6(5):259–67. Available from: https://pubmed.ncbi.nlm.nih.gov/33088809/
Gressenberger P, Pregartner G, Gary T, Wolf P, Kopera D. Platelet-rich Plasma for Androgenetic Alopecia Treatment: A Randomized Placebo-controlled Pilot Study. Acta Derm Venereol [Internet]. 2020 [cited 2024 May 25];100(15):1–7. Available from: https://pubmed.ncbi.nlm.nih.gov/32735021/
Verma K, Tegta G, Verma G, Gupta M, Negi A, Sharma R. A Study to Compare the Efficacy of Platelet-rich Plasma and Minoxidil Therapy for the Treatment of Androgenetic Alopecia. Int J Trichology [Internet]. 2019 Mar 1 [cited 2024 May 25];11(2):68–79. Available from: https://pubmed.ncbi.nlm.nih.gov/31007475/
Bajoria PS, Dave PA, Rohit RK, Tibrewal C, Modi NS, Gandhi SK, et al. Comparing Current Therapeutic Modalities of Androgenic Alopecia: A Literature Review of Clinical Trials. Cureus [Internet]. 2023 Aug 1 [cited 2024 May 25];15(7). Available from: /pmc/articles/PMC10469836/
Dai R, Yang X, Su Y, Wu X. Effectiveness and safety of the ablative fractional 2940-nm Er: YAG laser for the treatment of androgenetic alopecia. Lasers Med Sci [Internet]. 2024 Dec 1 [cited 2024 May 23];39(1). Available from: https://pubmed.ncbi.nlm.nih.gov/38724798/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Monika Stradczuk, Łukasz Mazurek, Barbara Rękas, Wojciech Mazurek, Mateusz Piętak, Barbara Kruczyk, Wojciech Kopacz, Joanna Olędzka, Zuzanna Czach, Dominika Bachurska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 187
Number of citations: 0
